Literature DB >> 9597668

Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment.

M C Mauri1, A Ferrara, L Boscati, S Bravin, F Zamberlan, M Alecci, G Invernizzi.   

Abstract

Plasma and platelet levels of 18 amino acids were measured in 29 outpatients (mean age +/- SD 47.41 +/- 10.85 years; 14 F, 15 M) affected by major depression (DSM IV) and in 28 healthy volunteers (mean age 42.46 +/- 14.19 years; 12 F, 16 M). Plasma and platelet levels of amino acids tended to be higher in depressed patients than in healthy controls. In particular, glutamate, taurine and lysine plasma levels and aspartate, serine and lysine platelet levels were significantly higher. Tryptophan/large neutral amino acids ratio (trp/LNAAs) was significantly lower in depressed patients. Fluvoxamine treatment did not influence plasma and platelet levels of amino acids or trp/LNAAs ratio.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597668     DOI: 10.1159/000026491

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  56 in total

1.  Relation of serum cholesterol, lipid, serotonin and tryptophan levels to severity of depression and to suicide attempts.

Authors:  L G Almeida-Montes; V Valles-Sanchez; J Moreno-Aguilar; R A Chavez-Balderas; J A García-Marín; J F Cortés Sotres; G Hheinze-Martin
Journal:  J Psychiatry Neurosci       Date:  2000-09       Impact factor: 6.186

Review 2.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 3.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

Review 4.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

Review 5.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

Review 6.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

7.  The effect of pyruvate on the development and progression of post-stroke depression: A new therapeutic approach.

Authors:  Dmitry Frank; Ruslan Kuts; Philip Tsenter; Benjamin F Gruenbaum; Yulia Grinshpun; Vladislav Zvenigorodsky; Ilan Shelef; Dmitry Natanel; Evgeny Brotfain; Alexander Zlotnik; Matthew Boyko
Journal:  Neuropharmacology       Date:  2019-05-31       Impact factor: 5.250

8.  Depression following traumatic brain injury in mice is associated with down-regulation of hippocampal astrocyte glutamate transporters by thrombin.

Authors:  Chun-Shu Piao; Ashley L Holloway; Sue Hong-Routson; Mark S Wainwright
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-14       Impact factor: 6.200

9.  Glutamatergic system abnormalities in posttraumatic stress disorder.

Authors:  Daisuke Nishi; Kenji Hashimoto; Hiroko Noguchi; Kei Hamazaki; Tomohito Hamazaki; Yutaka Matsuoka
Journal:  Psychopharmacology (Berl)       Date:  2015-08-22       Impact factor: 4.530

10.  Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder.

Authors:  Márcio Gerhardt Soeiro-de-Souza; Giacomo Salvadore; Ricardo Alberto Moreno; Maria Concepción Garcia Otaduy; Kalil T Chaim; Wagner F Gattaz; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.